AK Eisfeld

AML Physician Scientist, Director of the#BloomfieldCenter @OSUCCC. Working to overcome inequities in cancer care. #ASH-DEI/PrecisionMed. Science&Sparkling.

[Manel Esteller @ManelEsteller]

Whoa! Ecstatic that our @iannisaifantis1 @nyulangone @IRSantPau Nature Immunology @NatImmunol article about how #leukemia invades the #lung is also in the 99th percentile of all tracked articles of a similar age in all journals according to Altmetric. Recognition to rising stars @VarvaraParask and @ZiyanLin2352 !
https://t.co/VAbE7dDNy2

[AK Eisfeld @AkEisfeld]

Mentored by THE best!!! Congratulations, Megan and Linde!!

[Linde Miles @lindemilesphd]

Congrats to Miles lab trainee Megan Bones on receiving an @ASH_hematology Graduate Hematology Award! So incredibly proud of you!!

Thank you to @ASH_hematology for the impactful support. Congrats to Julie and the rest of the ASH awardees!

[Fieke Hoff @FiekeHoff]

Signaling mutations negate the favorable impact of NPM1 in older patients with AML treated with HMA/VEN. Just out in @AjHematology. Another great collaboration! @madanatyazan @beatalleukemia @AkEisfeld @LeukDocJZ and many others!
https://t.co/ccradbEAkO

[Varvara Paraskevopoulou @VarvaraParask]

Respiratory failure is a leading cause of death in AML.
It begins when leukemia infiltrates the lung. Almost nothing was known about what happens locally.
We looked.
🧵 @NatImmunol
🔗 https://t.co/OkhyRTRN4F

[Manel Esteller @ManelEsteller]

🚨 Excited to share our new Nature Immunology @NatImmunol paper! 🫁
How does acute myeloid #leukemia hijack the #lung and trigger #respiratory failure?
We found #AML cells drive #pulmonary remodeling via Galectin-9 & IL-33 signaling. And we identified drug treatments that can reverse it! 💊
Huge thanks to an amazing teamwork co-led with @iannisaifantis1 @VarvaraParask @nyugrossman
https://t.co/otxrK7d0Cq

[Fusion Conferences @Fusion_Conf]

📅 Mark Your Calendars!
The Hematologic Malignancies Conference is back for its second series!
🗓️ 01–04 November 2027
📍 Playa Mujeres, Mexico

Join leading PI's for an inspiring 4 day conference programme full of cutting edge science, meaningful discussions, and valuable networking opportunites.
🔔 Don't miss out! Sign up for updates and be the first to know when registration opens: https://t.co/xb1445PCBI
#FusionCancerResearch #FusionStemCells #FusionHumanDisease

[Mina L Xu @MinaXu7]

Looking forward to another phenomenal conference organized by @sanamloghavi @AkEisfeld @iannisaifantis1 #hemepath

[Iannis Aifantis @iannisaifantis1]

Excited to share our study on immune interactions in extramedullary (lung) acute myeloid leukemia (AML) out today at @NatImmunol !! Acute respiratory failure frequently occurs in AML due to leukemia infiltration of the lungs. The question is why and what can we do to suppress it. @VarvaraParask in the lab started this work by mapping AML:stromal and AML:immune cell interactions using scRNA-Seq and Visium/Xenium @10xGenomics spatial tools.
https://t.co/96RB7muFZK

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Many congratulations to this distinguished group of awardees , esp to @mkonople who is a role model for many of us in this field & has done so much to improve our understanding of AML biology & brought novel therapeutic options from the benchside to to clinic.
Go Marina 👏🏼💪🏻

[Ravi V. Bellamkonda @OhioStatePres]

A blood cancer can be a devastating diagnosis, but thanks to world-leading expertise at @OSUCCC_James, we’re working to be able to deliver the best treatment to every individual patient, every time. In this new “Pass the Mic,” Dr. Ann-Kathrin Eisfeld talks about how she and her colleagues are staying on the cutting edge in researching and treating rare leukemias and other blood disorders – and ultimately creating hope for patients and their loved ones.

[Marcos de Lima @DrMarcosdelima]

@AkEisfeld

[Kate Sears @MedwatchKate]

Hi friends, it's #AcuteMyeloidLeukemia Thursday! #EHA2026 edition 🎉🎉🎉

Here are Top Posts of the Week 🧵

1/ @sanamloghavi @lindemilesphd and @AkEisfeld on BRAF mutations in AML:
https://t.co/tIGMtyKvVj

[Naval Daver, M.D. @Daver_Leukemia]

Wonderful to celebrate with tremendous group of friends and warriors against leukemias! Congratulations Naveen and our international community for the collaboration and this breakthrough success! @LeukDocJZ @lane_andy @sanamloghavi @beatalleukemia @TapKadia @AkEisfeld

[Linde Miles @lindemilesphd]

New paper alert 🚨!! Such a fun collaboration with the absolute best @sanamloghavi @AkEisfeld dissecting the impact of BRAF mutations in AML!

[AK Eisfeld @AkEisfeld]

A reminder to think outside of the box when evaluating AML genomics- overlooking or not testing is consequential for our patients! Done with the best friends and collaborators @lindemilesphd @sanamloghavi @OSUHematology @OSUCCC_James

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Just out in @LeukemiaJnl 📣
With all hype around #RAS , We thought it’d be cool to characterize BRAF mutations in AML… led by the best collaborators in the business @lindemilesphd @AkEisfeld & teams
https://t.co/zJbcWLhcSO

[AK Eisfeld @AkEisfeld]

Non-canonical BRAF mutations in AML: underappreciated, enriched in AML-MR,..and maybe a therapeutic opportunity? Most importantly, a reminder to think outside of the box when evaluating AML genomics. Done with the best friends and collaborators @lindemilesphd @sanamloghavi

[AK Eisfeld @AkEisfeld]

Non-canonical BRAF mutations in AML: underappreciated, enriched in AML-MR,..and maybe a therapeutic opportunity? Most importantly, a reminder to think outside of the box when evaluating AML genomics. Done with the best friends and collaborators @lindemilesphd @sanamloghavi

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

🔴~1% of AML cases harbor BRAF mutations (canonical & non-canonical); mostly outside V600 hotspot & enriched in myelodysplasia-related AML (AML-MR)

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Just out in @LeukemiaJnl 📣
With all hype around #RAS , We thought it’d be cool to characterize BRAF mutations in AML… led by the best collaborators in the business @lindemilesphd @AkEisfeld & teams
https://t.co/zJbcWLhcSO

[Kimryn Rathmell @KimrynRathmell]

Honored to deliver a commencement address to the outstanding graduates at @cityofhope - the future is ready for you! Share your stories and let’s engage every person in building the next era in which we end cancer, together!

[Joshua Zeidner MD @LeukDocJZ]

Super proud of @beatalleukemia for delivering a fantastic presentation of the OPTI-AML data showing that Aza/Ven-14 is NOT equivalent to Aza/Ven-28 days at least for induction cycles 1-2. Highly impactful study from our BEAT AML team @bcutd_research